Moreover, the case describes a long-term remission with single-agent anti-CD38 antibody, daratumumab, in a chemotherapy-refractory case.<h4>Conclusion</h4>This case highlights the differing clinical manifestations of KSHV and the efficacy of immunotherapy in KSHV-associated primary effusion lymphoma. Here, CD38 is linked to primary effusion lymphoma.